TARS
Tarsus Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
68.88
close · 2026-08-13
value
38
cheaper than peers38
quality
73
stronger fundamentals73
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 4.90× | 81 |
| price to book | 8.60× | 26 |
| forward P/E | 33.15× | 23 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 69.4% | 69 |
| return on equity | -13.7% | 68 |
| operating margin | -11.4% | 65 |
| debt to equity | 25.6% | 42 |
4 of 4 measures available
Facts
| market cap | $3B |
| free cash flow | $67.5M |
| employees | 370 |
| first trade | 2020-10-16 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-10 |